Lb Pharmaceuticals (LBRX) Research & Development (2024 - 2026)

Lb Pharmaceuticals' Research & Development history runs 3 years deep, the most recent figure standing at $14.6 million for Q1 2026.

• In Q1 2026, Research & Development rose 328.09% year-over-year to $14.6 million; the TTM figure through Mar 2026 stood at $29.0 million (changed N/A YoY), while the FY2025 annual figure was $16.7 million, down 67.28% from the prior year.
• Research & Development was $14.6 million for Q1 2026 at Lb Pharmaceuticals, up from $8.5 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $14.6 million in Q1 2026 to a low of $376000.0 in Q4 2024.
• Historically, Research & Development has averaged $6.7 million across 3 years, with a median of $6.0 million in 2025.
• Biggest YoY gain for Research & Development was 2156.12% in 2025; the steepest drop was 77.32% in 2025.
• A 3-year view of Research & Development shows it stood at $376000.0 in 2024, then jumped by 2156.12% to $8.5 million in 2025, then soared by 72.64% to $14.6 million in 2026.
• The last three Research & Development figures came in at $14.6 million (Q1 2026), $8.5 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.